Significant Advances in Smoking Cessation
Recent research published in the Journal of the American Medical Association (JAMA) Internal Medicine highlights the major breakthroughs in smoking cessation treatment led by Achieve Life Sciences, Inc. (Nasdaq: ACHV). The ORCA-3 clinical trial revealed overwhelming evidence that cytisinicline effectively aids smokers in quitting, significantly increasing success rates compared to placebo treatments. This study involved 792 participants and showed promising results in reducing nicotine cravings among those taking cytisinicline.
Trial Findings Confirm Efficacy of Cytisinicline
The ORCA-3 trial is the second Phase 3 clinical study confirming the efficacy of cytisinicline. Participants reported enhanced quitting rates and reduced nicotine cravings noted at both 6 and 12 weeks of treatment. Achieve Life Sciences aims to file a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) by June 2025, marking a pivotal step in making cytisinicline available to those battling nicotine dependence.
Understanding Cytisinicline’s Mechanism
Cytisinicline, a plant-based alkaloid, works by binding to specific nicotine receptors in the brain, thereby alleviating withdrawal symptoms and cravings. Unlike other treatments, cytisinicline has demonstrated minimal side effects, making it highly tolerable. According to Dr. Cindy Jacobs, the President and Chief Medical Officer of Achieve Life Sciences, this selectivity significantly enhances patient comfort during the cessation process.
Impact of Smoking on Public Health
Smoking is a leading cause of preventable death, responsible for millions of fatalities globally. Achieve Life Sciences is committed to combating this epidemic through innovation and research. With more than 29 million adults in the U.S. smoking combustible cigarettes, effective treatments such as cytisinicline are essential in addressing this critical public health issue.
Expert Insights on Smoking Cessation
Dr. Nancy Rigotti, a renowned professor at Harvard Medical School, emphasizes the need for better treatment options for smokers. The findings from the ORCA-3 study suggest the potential of cytisinicline to reduce smoking-related health risks. As the company prepares for the NDA submission, the hope is that cytisinicline can become a standard part of the smoking cessation toolkit.
The Future of Cytisinicline
The Phase 3 ORCA-3 trial has solidified cytisinicline's position as a leading treatment option for nicotine dependence. Participants in the trial, who had an average age of 53 and a significant smoking history, noted improved outcomes while on the drug. Achieve Life Sciences has already seen success in earlier clinical phases, with two completed Phase 3 studies for smoking cessation and a Phase 2 study targeting vaping cessation.
Takeaways from the ORCA-3 Study
The ORCA-3 study not only reinforces cytisinicline’s therapeutic effectiveness but also addresses the critical need for an alternative to traditional cessation methods, which can often lead to adverse effects. The comprehensive nature of the trial includes biochemically verified continuous abstinence and reports after 24 weeks, providing a solid foundation for its future application.
Contact Achieve Life Sciences
For more information about Achieve Life Sciences and its innovative treatment approaches, interested parties can reach out via:
Email: ir@achievelifesciences.com
Phone: 425-686-1510
Frequently Asked Questions
What is cytisinicline?
Cytisinicline is a plant-based treatment developed to help individuals quit smoking by reducing cravings and withdrawal symptoms.
How does cytisinicline work?
It binds to the nicotine receptors in the brain, decreasing both the cravings for nicotine and the satisfaction derived from smoking.
What were the results of the ORCA-3 trial?
The ORCA-3 trial demonstrated significant increases in quitting rates and reductions in nicotine cravings compared to placebo.
When does Achieve Life Sciences plan to submit the NDA?
The company plans to submit the New Drug Application to the FDA in June 2025.
Why is cytisinicline considered a breakthrough?
It offers a highly selective and more tolerable alternative to existing smoking cessation treatments, potentially improving patient compliance and outcomes.
